Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. (Q51371120)
Jump to navigation
Jump to search
scientific article published in December 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. |
scientific article published in December 2011 |
Statements
1 reference
Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. (English)
1 reference
E Bosi
1 reference
G C Ellis
1 reference
C A Wilson
1 reference
P R Fleck
1 reference
1 December 2011
1 reference
13
1 reference
12
1 reference
1088-1096
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference